Wound-therapy specialist Reapplix APS says it's moving forward with US commercial activities to support its LeucoPatch wound-healing platform now that the results of a randomized trial assessing LeucoPatch to treat hard-to-treat diabetic foot ulcers are public. The results were presented at the American Diabetes Association 78th Scientific Sessions meeting in Orlando.
LeucoPatch, marketed in the US as 3CPatch, is a novel platform technology that provides cells and growth factors concentrated from a small sample of the patients’ own blood to produce...